XBiotech Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; financial statements are unaudited. XBiotech is a clinical-stage biopharmaceutical company developing True Human monoclonal antibodies. It reported no revenue and has never been profitable.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $7.8 million | $6.8 million; up 15% |
| General and administrative expense | $2.4 million | $1.4 million; up 71% |
| Operating loss | $10.2 million | $8.2 million |
| Net loss | $10.3 million | $8.1 million |
| Net loss per share, basic and diluted | $0.32 | $0.29 |
| Net cash used in operating activities | $9.9 million | $6.5 million |
| Net cash used in investing activities | $2.9 million | $0.6 million |
At March 31, cash and cash equivalents were $78.2 million, down from $91.1 million at December 31, 2015. Current assets were $79.8 million and current liabilities $6.6 million. Total liabilities were $6.6 million; the balance sheet lists no borrowings. Shareholders’ equity was $94.7 million and accumulated deficit was $140.9 million. The company reported no revenue, so operating margins are not meaningful. It had no material market-risk exposure or off-balance-sheet arrangements disclosed.
Investing cash use reflected $1.5 million of property and equipment purchases and $1.4 million of building construction spending. Construction in progress stood at $13.7 million. Management cited cash as its principal liquidity source and included a forward-looking belief that cash flows would meet needs for at least the next 12 to 24 months; actual funding needs depend on program progress and other developments.
Changes versus prior period
- Net loss widened by $2.1 million year over year, while operating expenses increased $2.0 million. R&D rose with clinical-trial activity and staffing; G&A growth included higher share-based compensation, salaries, and a $135,100 executive bonus.
- Operating cash use increased $3.4 million year over year, and investing cash use increased $2.3 million. No financing cash was received in Q1 2016, compared with $2.1 million in Q1 2015.
- Cash declined $12.8 million during Q1 2016. Common shares outstanding were 32.3 million at quarter-end, compared with 27.6 million weighted-average shares in Q1 2015.
Programs, outlook, risks, and unusual items
- Xilonix: The company said enrollment in its Phase III symptomatic colorectal cancer study was complete at 335 subjects and that endpoints were satisfactorily met. It submitted a Marketing Authorization Application to the European Medicines Agency in March 2016 and said possible revenue in 2017 would depend on approval and successful commercialization. The filing does not provide the detailed trial results.
- 514G3: Enrollment in Phase I for the Staphylococcus aureus bacteremia program was complete; the company said Phase II began after no dose-related toxicities were identified. It expected expansion into additional regions by the end of Q3 2016.
- Manufacturing facility: Austin construction advanced, but long-lead equipment procurement caused additional delays. The company anticipated completion in August 2016, validation thereafter, and production to support facility registration late in Q3 2016. These are forward-looking expectations.
- The company expected significant and increasing operating losses and stated it would need regulatory approval and successful commercialization to generate product revenue. It put the Pyoderma Gangrenosum regulatory path on hold indefinitely.
- Two purported securities class actions, filed in California state court and federal court in Texas, allege misleading statements concerning the European Xilonix Phase III trial. Both were in early procedural stages; plaintiffs sought unspecified damages. The company said no trial dates had been set.
- Share-based compensation was $1.8 million for the quarter. The filing reported approximately $4.6 million of unrecognized option compensation cost to be recognized over an estimated 2.16 years. No income-tax provision was recorded, with a full valuation allowance against deferred tax assets.
Investor verification priorities
- Verify the Xilonix Phase III data, the basis for the company’s endpoint statement, and the status and outcome of the EMA application and any other regulatory submissions.
- Track manufacturing-facility completion, validation, registration, and whether production milestones were achieved on the stated timeline.
- Assess cash burn, remaining cash runway, planned clinical and construction spending, and whether additional financing may be needed.
- Monitor progress and safety findings for 514G3 Phase II and any changes in development plans for other candidates.
- Follow the securities litigation and its potential financial or operational effects.